SEC Tracker
Get the app
BCTX · XBRL financial data

BriaCell Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BCTX's year ends in late July)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024†Jul 31, 2024Oct 31, 2024†Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Research and development6,8578,2577,6584,405*3,6655,6854,8107,110*6,6846,0545,96710,533*
General and administrative1,6461,5721,5721,362*1,4871,4851,5181,444*1,6391,4781,6542,047*
Total operating expenses8,5039,8299,2305,768*5,1537,1696,3288,554*8,3237,5317,62112,579*
Operating income (loss)(8,503)(9,829)(9,230)(5,768)*(5,153)(7,169)(6,328)(8,554)*(8,323)(7,531)(7,621)(12,579)*
Interest income19182160*13472733*48106219171*
Interest expense——————370*——300*
Net income (loss)6,002(11,295)1,716(1,214)*(5,802)(6,291)(6,127)(8,091)*(8,198)(7,222)(7,165)(12,320)*
Earnings per share, basic USD per share0.38(0.71)0.11(0.07)*(0.22)(2.33)(1.64)—(4.35)(2.58)(0.99)—
Earnings per share, diluted USD per share(0.50)(0.71)0.11—(0.22)(2.33)(1.64)—(4.35)(2.58)(0.99)—
Weighted average shares, basic thousands of shares15,98215,98215,98217,864*26,6412,7003,736—1,8842,8027,250—
Weighted average shares, diluted thousands of shares16,67515,98215,98217,171*26,6412,7003,736—1,8842,8027,250—
  • † Share count changed about 2x in the period ending 2024-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/12 in the period ending 2025-01-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (BCTX's year ends in late July)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024†Jul 31, 2024Oct 31, 2024†Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Cash and cash equivalents13,6466,2459368625,7925,01412,46010,4942,71429,9046,8809,852
Short-term investments———————7,3727,462—15,92410,688
Accounts receivable213015—————————
Total current assets18,40811,7425,5303,6548,2197,16314,78519,92711,34832,17925,39322,045
Property and equipment, net———388365342320297274251349320
Total assets18,61912,2316,2035,87210,4149,36417,00221,65013,07533,59427,07123,580
Total current liabilities1,0473,9246,7587,4614,9895,2314,3313,9783,3183,1863,5907,982
Accumulated deficit(74,651)(85,945)(84,230)(85,444)(91,246)(97,537)(103,664)(111,756)(119,953)(127,175)(134,339)(146,660)
Total liabilities and equity18,61912,2316,2035,87210,4149,36417,00221,65013,07533,59427,07123,580
Common shares outstanding (cover page) thousands of shares15,98215,98218,28536,18344,2043,7096,7761,8841,8847,2508,7008,732
  • † Share count changed about 2x in the period ending 2024-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/12 in the period ending 2025-01-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (BCTX's year ends in late July)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024†Jul 31, 2024Oct 31, 2024†Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Net income (loss)6,002(11,295)1,716(1,214)*(5,802)(6,291)(6,127)(8,091)*(8,198)(7,222)(7,165)(12,320)*
Stock-based compensation534500392378*2672852250*295286432*118*
Net cash from operating activities(7,605)(7,401)*(5,084)*(4,036)*(6,955)(5,920)*(7,163)*(8,132)*(7,705)(7,967)*(7,020)*(5,959)*
Purchases of property and equipment———year only———————0*
Net cash from investing activities———(457)*(75)(75)*(105)*(7,391)*(75)7,282*(16,003)*4,991*
Proceeds from issuing common stock———year only11,6674,689*14,714*13,557*——0*3,941*
Proceeds from issuing equity———————year only———year only
Net cash from financing activities———year only11,9605,217*14,714*13,557*——0*3,941*
Net change in cash(7,605)(7,401)*(5,309)*(74)*4,930(779)*7,447*(1,966)*(7,780)27,190*(23,023)*2,972*
  • † Share count changed about 2x in the period ending 2024-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/12 in the period ending 2025-01-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
BriaCell Therapeutics9,852not reported(5,959)*8.7M3.4 quarters 10-KJul 31, 2026
Abvc Biopharma32not reported(244)*26.7M0.4 quarters 10-QJun 30, 2026
Karyopharm Therapeutics54,98033,432(24,931)*22.7M2.6 quarters 10-QJun 30, 2026
Atara Biotherapeutics3,221630(3,338)*10.0M3.0 quarters 10-QJun 30, 2026
Annovis Bio18,7290*(21,914)*42.6M0.9 quarters 10-QJun 30, 2026
CervoMed22,4630(6,918)*15.1M3.6 quarters 10-QJun 30, 2026
Grace Therapeutics13,756not reported(3,221)21.0M4.3 quarters 10-QJun 30, 2026
Actuate Therapeutics4,426not reported(4,405)*24.0M1.0 quarters 10-QJun 30, 2026
Kezar Life Sciences66,229not reported(7,445)7.4M8.9 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.